Acepodia (KY) announced on the 8th that their developed cell therapy drug ACE1831 achieved the endpoints in the first dose group of the first phase of clinical trials. Five participants with non Hodgkin's lymphoma were enrolled in this dose group, among whom three completed the safety observation period defined in the clinical trial protocol and met the criteria for safety data review during dose escalation.
This clinical data from Acepodia was released during a conference held by William Blair & Company on the East Coast of the United States on the 7th. CEO of Acepodia, Jason Hsiao, stated that in terms of safety and tolerability, all participants in this group did not experience any severe adverse events related to ACE1831, nor did they develop cytokine release syndrome (CRS) or acute graft-versus-host disease (GvHD) related to ACE1831.
This clinical trial is a multicenter, multinational study aimed at evaluating the safety and efficacy of ACE1831 in adult patients with relapsed or refractory CD20-positive B-cell lymphoma, which is an immune cell marker used for diagnosing and treating B-cell-related diseases.
Acepodia stated that the Antibody-Cell Conjugation (ACC) technology is derived from Nobel laureate Dr. Carolyn Bertozzi's invention of bioorthogonal chemistry. This technology does not require genetic editing and allows scientists to use live cell-compatible chemistry to link antibodies to cells, enhancing immune cell recognition and killing ability against cancer cells. It integrates T-cell engagers and cell therapy. The Antibody-Cell Conjugation (ACC) and γδ2T cell technology platforms have the potential to overcome the problems encountered by existing immune checkpoint inhibitors, such as T-cell exhaustion or failure of tumor antigen recognition mechanisms. It is expected to enhance the function of immune cells and further improve treatment efficacy.
Resource (Mandarin):
